TriSalus Life Sciences, Inc.TLSI決算レポート
Nasdaq · ヘルスケア · 外科用及び医療用器具
TriSalus Life Sciences, Inc.は臨床段階のバイオテクノロジー企業で、免疫腫瘍学と介在腫瘍学のソリューション開発に注力しています。肝臓がん、膵臓がんなど治療が難しい固形がん患者の治療効果を高める独自の標的薬物送達技術を開発し、主に北米市場で事業を展開しています。
主要株主
| 株主 | 保有比率 | 株数 | 変動 | 基準日 |
|---|---|---|---|---|
| MedTech Acquisition Sponsor LLC | 84.50% | 6.3M | — | 2023-07-06 |
| Frankenius Equity AB | 24.10% | 6.4M | — | 2023-08-21 |
| Mats Wahlstr m | 10.40% | 2.7M | — | 2023-08-21 |
| David J. Matlin | 8.20% | 2.3M | — | 2023-08-21 |
| James J. Pallotta | 6.24% | 1.9M | — | 2024-12-04 |
| Unique Diamond Investments Limited | 5.90% | 1.5M | — | 2023-08-29 |
| Christopher Dewey | 5.60% | 1.5M | — | 2023-08-21 |
| Michael P. Stansky | 5.30% | 1.4M | — | 2023-08-22 |
| Gene R. McGrevin | 5.30% | 1.4M | — | 2023-08-21 |
| Magnetar Financial LLC | 4.20% | 1.2M | ▼ -3.80pp | 2023-08-14 |
インサイダー取引
Net 90d: +$1.65M · buys $1.79M / sells $134.4K期間:
種別:
役職:
| インサイダー | 役職 | 種別 | ||||
|---|---|---|---|---|---|---|
| 2026-03-17 | Szela Mary T | CEO and President | Sell (open market) | 15.9K | $3.85 | $61.4K |
| 2026-03-16 | Jodi Devlin | Chief of Clinical Operations | Sell (open market) | 273 | $4.12 | $1.1K |
| 2026-03-16 | Richard Marshak | Chief Commercial Officer | Sell (open market) | 419 | $4.12 | $1.7K |
| 2026-03-16 | Cox Bryan F. | Chief of Research | Sell (open market) | 579 | $4.12 | $2.4K |
| 2026-03-16 | Jennifer Stevens | Chief Regulatory Officer | Sell (open market) | 774 | $4.12 | $3.2K |
| 2026-03-12 | Jodi Devlin | Chief of Clinical Operations | Sell (open market) | 1.8K | $4.09 | $7.2K |
| 2026-03-12 | Richard Marshak | Chief Commercial Officer | Sell (open market) | 1.6K | $4.09 | $6.5K |
| 2026-03-12 | Cox Bryan F. | Chief of Research | Sell (open market) | 1.5K | $4.09 | $6.0K |
| 2026-03-12 | Jennifer Stevens | Chief Regulatory Officer | Sell (open market) | 1.6K | $4.09 | $6.3K |
| 2026-03-11 | Jodi Devlin | Chief of Clinical Operations | Sell (open market) | 1.2K | $4.13 | $4.8K |
1–10 of 20
1 / 2 ページ